| Craig Venter |
|Born||October 14, 1946|
|Alma mater||University of California (San Diego)|
|Founder of||Human Genome Sciences|
John Craig Venter is an American biotechnologist and businessman with an interest in patenting genes. He is known for leading the first draft sequence of the human genome and assembled the first team to transfect a cell with a synthetic chromosome. His work has been compared in importance with "the equivalent of the development of nuclear weapons"
Venter founded Celera Genomics, The Institute for Genomic Research (TIGR) and the J. Craig Venter Institute (JCVI), where he currently serves as CEO. He was the co-founder of Human Longevity Inc. and Synthetic Genomics. He was listed on Time magazine's 2007 and 2008 Time 100 list of the most influential people in the world.
Early life and education
Venter was born in Salt Lake City, Utah, the son of Elizabeth and John Venter. In his youth, he did not take his education seriously, preferring to spend his time on the water in boats or surfing.  According to his biography, A Life Decoded, he was said to never be a terribly engaged student, having Cs and Ds on his eighth-grade report cards. He graduated from Mills High School in Millbrae, California.
Although he opposed the Vietnam War, Venter was drafted and enlisted in the United States Navy where he worked in the intensive-care ward of a field hospital. While in Vietnam, he attempted suicide by swimming out to sea, but changed his mind more than a mile out. Being confronted with severely injured and dying marines on a daily basis instilled in him a desire to study medicine, although he later switched to biomedical research.
Venter began his college education at a community college, College of San Mateo in California, and later transferred to the University of California, San Diego, where he studied under biochemist Nathan O. Kaplan. He received a BS in biochemistry in 1972 and a PhD in physiology and pharmacology in 1975 from UCSD.
While an employee of the NIH, Venter learned how to identify mRNA and began to learn more about those expressed in the human brain. The short cDNA sequence fragments he was interested in are called expressed sequence tags, or ESTs. The NIH Office of Technology Transfer and Venter decided to take the ESTs discovered by others in an attempt to patent the genes identified based on studies of mRNA expression in the human brain. When Venter disclosed this strategy during a Congressional hearing, a firestorm of controversy erupted. The NIH later stopped the effort and abandoned the patent applications it had filed, following public outcry.
Human Genome Project
Venter was passionate about the power of genomics to radically transform healthcare. Venter believed that shotgun sequencing was the fastest and most effective way to get useful human genome data. The method was rejected by the Human Genome Project however, since some geneticists felt it would not be accurate enough for a genome as complicated as that of humans, that it would be logistically more difficult, and that it would cost significantly more.
Venter viewed the slow pace of progress in the Human Genome project as an opportunity to continue his interest in patenting genes, so he sought funding from the private sector to start Celera Genomics. The company planned to profit from their work by creating genomic data to which users could subscribe for a fee. The goal consequently put pressure on the public genome program and spurred several groups to redouble their efforts to produce the full sequence. Venter's effort won him renown as he and his team at Celera Corporation shared credit for sequencing the first draft human genome with the publicly funded Human Genome Project.
In 2000, Venter and Francis Collins of the National Institutes of Health and U.S. Public Genome Project jointly made the announcement of the mapping of the human genome, a full three years ahead of the expected end of the Public Genome Program. The announcement was made along with U.S. President Bill Clinton, and UK Prime Minister Tony Blair.
On 15 February 2001, the Human Genome Project consortium published the first Human Genome in the journal Nature, followed one day later by a Celera publication in Science. Despite some claims that shotgun sequencing was in some ways less accurate than the clone-by-clone method chosen by the Human Genome Project, the technique became widely accepted by the scientific community.
Venter was fired by Celera in early 2002. According to his biography, Venter was fired due to a conflict with the main investor, Tony White, specifically barring him from attending the White House ceremony celebrating the achievement of sequencing the human genome.
Global Ocean Sampling Expedition
The Global Ocean Sampling Expedition (GOS) is an ocean exploration genome project with the goal of assessing the genetic diversity in marine microbial communities and to understand their role in nature's fundamental processes. Begun as a Sargasso Sea pilot sampling project in August 2003, Venter announced the full Expedition on 4 March 2004. The project, which used Venter's personal yacht, Sorcerer II, started in Halifax, Canada, circumnavigated the globe and returned to the U.S. in January 2006.
In June 2005, Venter co-founded Synthetic Genomics, a firm dedicated to using modified microorganisms to produce clean fuels and biochemicals. In July 2009, ExxonMobil announced a $600 million collaboration with Synthetic Genomics to research and develop next-generation biofuels. Venter continues to work on the creation of engineered diatomic microalgae for the production of biofuels.
Venter is seeking to patent the first partially synthetic species possibly to be named Mycoplasma laboratorium. There is speculation that this line of research could lead to producing bacteria that have been engineered to perform specific reactions, for example, produce fuels, make medicines, combat global warming, and so on.
In May 2010, a team of scientists led by Venter became the first to successfully create what was described as "synthetic life". This was done by synthesizing a very long DNA molecule containing an entire bacterium genome, and introducing this into another cell, analogous to the accomplishment of Eckard Wimmer's group, who synthesized and ligated an RNA virus genome and "booted" it in cell lysate. written into its DNA to identify it as synthetic and to help trace its descendants. The watermarks include
- Code table for entire alphabet with punctuations
- Names of 46 contributing scientists
- Three quotations
- The secret email address for the cell.
On March 25, 2016 Venter reported the creation of Syn 3.0, a synthetic genome having the fewest genes of any freely living organism (473 genes). Their aim was to strip away all nonessential genes, leaving only the minimal set necessary to support life. This stripped-down, fast reproducing cell is expected to be a valuable tool for researchers in the field.
In August 2018, Venter retired as chairman of the board, saying he wanted to focus on his work at the J. Craig Venter Institute. He will remain as a scientific advisor to the board.
J. Craig Venter Institute
Venter is currently the chief executive officer of the J. Craig Venter Institute, a nonprofit which conducts research in synthetic biology. Venter founded the organization in 2006. It has facilities in La Jolla and in Rockville, Maryland and employs over 200 people.
Individual human genome
On September 4, 2007, a team led by Sam Levy published one of the first genomes of an individual human—Venter's own DNA sequence. Some of the sequences in Venter's genome are associated with wet earwax, increased risk of antisocial behavior, Alzheimer's and cardiovascular diseases. This publication was especially interesting because it attempted to separate the two haplotypes (the two copies of each chromosome), although it only accomplished this in a limited way. The genome as published only had 3 billion bases, rather than the full 6 billion that would comprise a fully diploid sequence. Another 10 years passed before the first haplotype-resolved human genomes began to appear.
The Human Reference Genome Browser is a web application for the navigation and analysis of Venter's recently published genome. The HuRef database consists of approximately 32 million DNA reads sequenced using microfluidic Sanger sequencing, assembled into 4,528 scaffolds and 4.1 million DNA variations identified by genome analysis. These variants include single-nucleotide polymorphisms (SNPs), block substitutions, short and large indels, and structural variations like insertions, deletions, inversions and copy number changes.
The browser enables scientists to navigate the HuRef genome assembly and sequence variations, and to compare it with the NCBI human build 36 assembly in the context of the NCBI and Ensembl annotations. The browser provides a comparative view between NCBI and HuRef consensus sequences, the sequence multi-alignment of the HuRef assembly, Ensembl and dbSNP annotations, HuRef variants, and the underlying variant evidence and functional analysis. The interface also represents the haplotype blocks from which diploid genome sequence can be inferred and the relation of variants to gene annotations. The display of variants and gene annotations are linked to external public resources including dbSNP, Ensembl, Online Mendelian Inheritance in Man (OMIM) and Gene Ontology (GO).
Users can search the HuRef genome using HUGO gene names, Ensembl and dbSNP identifiers, HuRef contig or scaffold locations, or NCBI chromosome locations. Users can then easily and quickly browse any genomic region via the simple and intuitive pan and zoom controls; furthermore, data relevant to specific loci can be exported for further analysis.
Human Longevity, Inc.
On March 4, 2014 Venter and co-founders Peter Diamandis and Robert Hariri announced the formation of Human Longevity, Inc., a company focused on extending the healthy, "high performance" human lifespan. At the time of the announcement the company had already raised $70 million in venture financing, which was expected to last 18 months. Venter was the chairman and chief executive officer (CEO) until May 2018, when he retired. The company said that it plans to sequence 40,000 genomes per year, with an initial focus on cancer genomes and the genomes of cancer patients.
Human Longevity filed a lawsuit in 2018 against Venter, accusing him of stealing trade secrets. Allegations were made stating that Venter had departed with his company computer that contained valuable information that could be used to start a competing business. The lawsuit was ultimately dismissed by a California Judge on the basis that Human Longevity were unable to present a case that met the legal threshold required for a company, or individual, to sue when its trade secrets have been stolen.
Human Longevity's mission is to extend healthy human lifespan by the use of high-resolution big data diagnostics from genomics, metabolomics, microbiomics, and proteomics, and the use of stem cell therapy.
- https://www.bitchute.com/video/KifMmno9ByOQ/ Dr. Charles Morgan at minute 27:52.
- 'Artificial life' breakthrough announced by scientists, BBC, 21 May 2010. http://news.bbc.co.uk/2/hi/science_and_environment/10138849.stm